Genesys Capital invests in $80 ml Series C financing of Naurex
Naurex Inc, a U.S.-based biopharmaceutical company that develops novel drugs for diseases of the central nervous system, has closed a US$80 million Series C financing. Investors in the round included existing backer Genesys Capital, a Canadian life sciences venture capital firm. Adams Street Partners, Baxter Ventures, Druid BioVentures, Latterell Venture Partners, PathoCapital and Savitr Capital were among the other investors. Naurex, which is headquartered in Evanston, Illinois, said the deal's proceeds will support the ongoing clinical development of its lead compounds, including GLYX-13, which treats major depressive disorder.
3 December 2014•4 mins read
